Author

Chiriva-Internati M

Associate Professor, University of Texas, Mdanderson Cancer Center - Cited by 7,035 - immunology

Biography

Chiriva-Internati  M working with the Department of Internal Medicine, Texas Tech University, Lubbock, TX, USA. Specialization cloning-techniques, cloning-vectors, genetically-modified-organism, cybridization, cloning sequencing, and has published article entitled “Improving AAV Gene Therapy: Graduating From Transgene Expression “Everywhere, All The Time” To “Disease-Specific”
Title
Cited by
Year
Celiac disease: From pathophysiology to treatment
I Parzanese, D Qehajaj, F Patrinicola, M Aralica, M Chiriva-Internati, ...World journal of gastrointestinal pathophysiology 8 (2), 27, 2017201
277
2017
Cancer cells exploit notch signaling to redefine a supportive cytokine milieu
M Colombo, L Mirandola, M Chiriva-Internati, A Basile, M Locati, E Lesma, ...Frontiers in immunology 9, 1823, 2018201
50
2018
Evolving notions on immune response in colorectal cancer and their implications for biomarker development
F Grizzi, G Basso, EM Borroni, T Cavalleri, P Bianchi, S Stifter, ...Inflammation Research 67, 375-389, 2018201
41
2018
Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy
L Mirandola, E Pedretti, JA Figueroa, R Chiaramonte, M Colombo, ...Oncotarget 8 (43), 74378, 2017201
21
2017
Role of MSC-derived galectin 3 in the AML microenvironment
PP Ruvolo, VR Ruvolo, JK Burks, YH Qiu, RY Wang, EJ Shpall, ...Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1865 (7), 959-969, 2018201
19
2018
The kidney, COVID-19, and the chemokine network: an intriguing trio
G Taverna, S Di Francesco, EM Borroni, D Yiu, E Toniato, S Milanesi, ...International Urology and Nephrology 53, 97-104, 2021202
16
2021
Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17
JP Mattila, L Mirandola, M Chiriva‐InternatiJournal of Biomedical Materials Research Part B: Applied Biomaterials 107 (1 …, 2019201
13
2019
The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma
CA Schutt, L Mirandola, JA Figueroa, DD Nguyen, J Cordero, K Bumm, ...Oncotarget 8 (59), 100280, 2017201
12
2017
CdS quantum dot-chitosan-anti SP17 nanohybrid as a potential cancer biomarker
L Liu, L Mirandola, M Chiriva-Internati, J ChaudhuriMaterials Letters 199, 5-8, 2017201
11
2017
Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study
LL Brunette, PY Mhawech-Fauceglia, L Ji, JG Skeate, HE Brand, ...BMC cancer 18 (1), 1-12, 2018201
9
2018
Computer-aided assessment of the extra-cellular matrix during pancreatic carcinogenesis: a pilot study
F Grizzi, S Fiorino, D Qehajaj, A Fornelli, C Russo, D De Biase, M Masetti, ...Journal of translational medicine 17, 1-, 20120
9
2019
Fusobacterium nucleatum and the Immune System in Colorectal Cancer
EM Borroni, D Qehajaj, FM Farina, D Yiu, RS Bresalier, M Chiriva-Internati, ...Current Colorectal Cancer Reports 15, 149-15, 2019201
6
2019
Galectin-3C combination therapy for human cancer
M Chiriva-Internati, E Cobos, C JohnUS Patent 9,744,212, 2017201
5
2017
A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade
A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p8 kinase blockadeL Mirandola, M Chiriva-Internati, R Bresalier, L Piccotti, F Grizzi, ...Journal of translational medicine 17 (1), 1-9, 2019201
3
2019
Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
M Chiriva-Internati, L Mirandola, R Bresalier, S Dahlbeck, JA Figueroa, ...Journal of Clinical Oncology 37 (15_suppl), e15748-e15748, 01901
2
2019
Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy
L Mirandola, M Chiriva-Internati, R Bresalier, FM Marincola, JA Figueroa, ...Translational Medicine Communications 4 (1), 1-10, 01901
2
2019
Compositions and methods for treating cardiovascular diseases using foxp3
M Chiriva-InternatiUS Patent App. 15/053,171, 01601
2
2016
Immunohistochemical features of the pseudomyxoma peritonei microenvironment: an opportunity for clinicians
F Grizzi, FCM Cananzi, S Battista, T Brambilla, D Qehajaj, ...Analytical and Quantitative Cytopathology and Histopathology 40 (3), 109-115, 01801
2
2018
Abstract LB148: Gamma delta T cells engineered with a chimeric PD-1 receptor effectively control PD-L1 positive tumors in vitro and in vivo with minimal toxicities
A Barber, X Wang, A Gopisetty, L Mirandola, M Chiriva-InternatiCancer Research 81 (13_Supplement), LB148-LB148, 010
2
2021
Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination …
M Chiriva-Internati, JA Figueroa, E CobosUS Patent App. 4/992,73, 20620
1
2016

Referred From: https://scholar.google.com/citations?hl=en&user=tEhtNnoAAAAJ

Cited by
Citations 7035
h-index 50
i10-index 128
Open Access Journals